Blueprint Medicines Overview
Blueprint Medicines Target Price
Explore Blueprint Medicines's target price with historical charts and peer comparisons.
Get informed when a big investor buys or sells
+ FollowShare Price
$129.46
Average Target Price
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-06-03 | GuggenheimMichael Schmidt | $132 |  2% upside |  |
| 2025-03-07 | Scotiabank | $150 | 15.9% upside | |
| 2024-10-31 | NeedhamAmi Fadia | $135 | 4.3% upside | |
| 2024-10-24 | UBSDavid Dai | $88 |  32% downside | |
| 2024-09-19 | Stifel NicolausBradley Canino | $155 | 19.7% upside | |
| 2024-08-01 | OppenheimerMatthew Biegler | $130 | 0.4% upside | |
| 2024-07-29 | BarclaysPeter Lawson | $105 | 18.9% downside | |
| 2024-07-08 | OppenheimerMatthew Biegler | $125 | 3.4% downside | |
| 2024-05-06 | Leerink PartnersAndrew Berens | $97 | 25.1% downside | |
| 2024-05-03 | Raymond JamesChristopher Raymond | $104 | 19.7% downside | |
| 2024-05-03 | H.C. WainwrightAndrew Fein | $135 | 4.3% upside | |
| 2022-12-14 | Needham | $60 | 53.7% downside | |
| 2022-11-02 | H.C. WainwrightAndrew Fein | $70 | 45.9% downside | |
| 2022-09-06 | OppenheimerMatthew Biegler | $90 | 30.5% downside | |
| 2022-08-17 | Wells FargoDerek Archila | $41 | 68.3% downside | |
| 2022-05-18 | Piper SandlerChristopher Raymond | $65 | 49.8% downside | |
| 2022-02-01 | Morgan StanleyMichael Ulz | $92 | 28.9% downside | |
| 2022-01-03 | GuggenheimMichael Schmidt | $122 | 5.8% downside | |
| 2021-11-09 | Raymond JamesDane Leone | $133 | 2.7% upside | |
| 2021-07-29 | Goldman SachsSalveen Richter | $147 | 13.5% upside | |
| 2021-06-17 | Canaccord GenuityArlinda Lee | $120 | 7.3% downside | |